Hillsborough, NJ, United States of America

Gregory E Koll

USPTO Granted Patents = 11 (Patent Applications = 3)

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 7 (Patent Applications = 7)

Average Co-Inventor Count = 3.5

ph-index = 4

Forward Citations = 32(Granted Patents)

Company Filing History:

Johnson & Johnson Consumer Inc.

Years Active: 2012-2024

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12083218 - Soft chewable dosage form (2024-09-10),

2. 11679081 - Chewing gum comprising nicotine (2023-06-20),

3. 11141375 - Soft chewable dosage form (2021-10-12),

4. 10500155 - Lozenge dosage form having a disintegrative tablet portion and a candy glass shell portion (2019-12-10),

5. 10493026 - Process for making tablet using radiofrequency and lossy coated particles (2019-12-03),

6. 9789066 - Process for making tablet using radiofrequency and lossy coated particles (2017-10-17),

7. 8865204 - Manufacture of lozenge product with radiofrequency (2014-10-21),

8. 8784781 - Manufacture of chewing gum product with radiofrequency (2014-07-22),

9. 8658200 - Flavoring of drug-containing chewing gums (2014-02-25),

10. 8343533 - Manufacture of lozenge product with radiofrequency (2013-01-01),

11. 8323683 - Flavoring of drug-containing chewing gums (2012-12-04),

Title: The Innovations of Gregory E. Koll: A Visionary in Pharmaceutical Technology

Introduction: Gregory E. Koll, an inventive mind located in Hillsborough, NJ, has made significant contributions to the field of pharmaceuticals, boasting an impressive portfolio of 10 patents. His work primarily focuses on innovative dosage forms that enhance the effectiveness of active pharmaceutical ingredients while addressing critical health issues.

Latest Patents: Among his latest breakthroughs is the development of a soft chewable dosage form. This invention incorporates a first active pharmaceutical ingredient encapsulated in a lipid material, which is embedded within the soft chewable matrix. Furthermore, this formulation includes at least a second active pharmaceutical ingredient, providing a dual-action method aimed at treating individuals suffering from diseases or disorders in the gastrointestinal tract. This innovation exemplifies his commitment to improving patient compliance and therapeutic outcomes.

Career Highlights: Gregory has played pivotal roles in esteemed companies, including McNeil-PPC, Inc. and Johnson & Johnson Consumer Inc. His tenure at these organizations has enabled him to translate innovative concepts into tangible healthcare solutions, marking him as a vital contributor to the pharmaceutical industry.

Collaborations: Throughout his career, Gregory has collaborated with notable colleagues such as Christopher Szymczak and Gerard P. McNally. These partnerships have fostered a dynamic environment that encourages the exchange of ideas and advancements in pharmaceutical technologies.

Conclusion: Gregory E. Koll stands as a prominent figure in the realm of pharmaceuticals, distinguishing himself through his innovative patents and collaborative efforts. His dedication to enhancing drug delivery systems and addressing critical health needs showcases the impact of his work on the future of healthcare. Gregory's inventions not only pave the way for improved treatment options but also reinforce the importance of innovation in medicine.

This text is generated by artificial intelligence and may not be accurate.